Glenmark Pharmaceuticals’ Europe operations reported a dull third quarter but the firm expects a pick up in the business going forward, aided in part by a settlement pertaining to Salmex (fluticasone/salmeterol), its partnered generic version of GlaxoSmithKline’s Seretide Accuhaler dry powder inhaler.
Glenmark said that the settlement agreement concluded with GSK will allow it and Polish partner Celon Pharma to sell...